Lesson plan

Iptacopan

Iptacopan, sold under the brand name Fabhalta, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria. It is a complement factor B inhibitor that was developed by Novartis. It is taken by mouth. Iptacopan was approved for medical use in the United States in December 2023, and in the European Union in May 2024. The US Food and Drug Administration considers it to be a first-in-class medication.

Back to article

Article summary

Iptacopan, sold under the brand name Fabhalta, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria. It is a complement factor B inhibitor that was developed by Novartis. It is taken by mouth. Iptacopan was approved for medical use in the United States in December 2023, and in the European Union in May 2024. The US Food and Drug Administration considers it to be a first-in-class medication.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.